# US 2026/0266829 A1 · C3F Assay

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0266829 A1
- Document ID: US20260266829A1
- Status: Published application
- Kind: A1
- Application number: 19/167,381
- Filed: 2024-03-22
- Published: 2026-09-10
- Earliest claimed: 2023-03-22
- Assignees: Nordic Bioscience A/S
- Applicants: Nordic Bioscience A/S
- Inventors: Rasmus Sund Petersen; Nicholas Willumsen; Morten Asser Karsdal
- Web page: https://patentgrep.com/patent/US20260266829A1

## CPC

- G01N 33/577: involving monoclonal antibodies {binding reaction mechanisms characterised by the use of monoclonal antibodies (G01N33/5302 - G01N33/576 take precedence)}
- C07K 7/00: Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K 16/18: against material from animals or humans
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 33/5752: of the lungs
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2800/105: Osteoarthritis, e.g. cartilage alteration, hypertrophy of bone
- G01N 2800/7028: Cancer
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein are methods of immunoassay for detecting a fibroblast activation protein (FAP) generated fragment of type III collagen in a patient sample, and the use thereof for detecting and/or monitoring cancer or arthritis or a particular level of severity thereof in a patient. Also described are monoclonal antibodies and assay kits for use in said methods of immunoassay.

## Claims

### Claim 1

A method of immunoassay, said method comprising;
i) contacting a patient sample with a monoclonal antibody that specifically binds to the N-terminus amino acid sequence AGPAGAPGPA (SEQ ID NO: 1); and
ii) detecting and determining the amount of binding between said monoclonal antibody and peptides in the sample.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the method is a method of immunoassay for detecting and/or monitoring a cancer or a particular level of severity thereof in a patient, the method further comprising;
iii) correlating said amount of binding with values associated with normal healthy subjects and/or values associated with known disease severity and/or values obtained from said patient at a previous time point and/or with a predetermined cut-off value.

### Claim 3 (depends on 2)

The method as claimed in claim 2, wherein the cancer is a lung cancer.

### Claim 4 (depends on 3)

The method as claimed in claim 3, wherein the lung cancer is a non-small cell lung cancer.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein the method is a method of immunoassay for detecting and/or monitoring an arthritis or a particular level of severity thereof in a patient, the method further comprising;
iii) correlating said amount of binding with values associated with normal healthy subjects and/or values associated with known disease severity and/or values obtained from said patient at a previous time point and/or with a predetermined cut-off value.

### Claim 6 (depends on 5)

The method as claimed in claim 5, wherein the arthritis is spondyloarthritis.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein the patient sample is selected from blood, plasma or serum.

### Claim 8 (depends on 1)

The as claimed in claim 1, wherein the monoclonal antibody does not specifically bind to a peptide having the N-terminus amino acid sequence PAGPAGAPGPA (SEQ ID NO: 2).

### Claim 9 (depends on 1)

The method as claimed in claim 1, wherein the monoclonal antibody does not specifically bind to a peptide having the N-terminus amino acid sequence GPAGAPGPA (SEQ ID NO: 3).

### Claim 10 (depends on 1)

The method as claimed in claim 1, wherein the monoclonal antibody is raised against a synthetic peptide having the N-terminus amino acid sequence AGPAGAPGPA (SEQ ID NO: 1).

### Claim 11 (depends on 1)

The method as claimed in claim 1, wherein the immunoassay is a competition assay or a sandwich assay.

### Claim 12 (depends on 1)

The method as claimed in claim 1, wherein the immunoassay is a radio-immunoassay or an enzyme-linked immunosorbent assay.

### Claim 13

A monoclonal antibody that specifically binds to the N-terminus amino acid sequence AGPAGAPGPA (SEQ ID NO: 1).

### Claim 14 (depends on 13)

The monoclonal antibody as claimed in claim 13, wherein the monoclonal antibody does not specifically bind to a peptide having the N-terminus amino acid sequence PAGPAGAPGPA (SEQ ID NO: 2).

### Claim 15 (depends on 13)

The monoclonal antibody as claimed in claim 13, wherein the monoclonal antibody does not specifically bind to a peptide having the N-terminus amino acid sequence GPAGAPGPA (SEQ ID NO: 3).

### Claim 16 (depends on 13)

The monoclonal antibody as claimed in claim 13, wherein the monoclonal antibody is raised against a synthetic peptide having the N-terminus amino acid sequence AGPAGAPGPA (SEQ ID NO: 1).

### Claim 17 (depends on 13)

An immunoassay kit comprising a monoclonal antibody as claimed in claim 13, and at least one of:
a streptavidin coated well plate;
a biotinylated peptide AGPAGAPGPA-L-Biotin (SEQ ID NO: 14), wherein L is an optional linker;
a secondary antibody for use in a sandwich immunoassay;
a calibrator protein comprising the N-terminus amino acid sequence AGPAGAPGPA (SEQ ID NO: 1);
an antibody biotinylation kit
an antibody HRP labelling kit; or
an antibody radiolabelling kit.
